HIV-1 reverse transcriptase mutants resistant to nonnucleoside reverse transcriptase inhibitors do not adversely affect DNA synthesis: Pre-steady-state and steady-state kinetic studies

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 4, 2006, Pages 405-411

  Domaoal, Robert A ^a,b   Bambara, Robert A ^a   Demeter, Lisa M ^a,c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

DNA polymerization; HIV 1 reverse transcriptase; K103N; NNRTI resistance; P236L; V106A

Indexed keywords

DEOXYGUANOSINE TRIPHOSPHATE; DNA; MUTANT PROTEIN; RIBONUCLEASE H; RNA; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBIOTIC RESISTANCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERIZATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; VIRUS MUTANT; WILD TYPE;

BASE SEQUENCE; DNA PRIMERS; DNA REPLICATION; DRUG RESISTANCE, VIRAL; HIV-1 REVERSE TRANSCRIPTASE; KINETICS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33745886260     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000222288.90201.33     Document Type: Article

References (39)

1. Goff SP. Retroviral reverse transcriptase: synthesis, structure, and function. J Acquir Immune Defic Syndr. 1990;3(8):817-831.
2. Kohlstaedt LA, Wang J, Friedman JM, et al. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992;256(5065):1783-1790.
3. Esnouf R, Ren J, Ross C, et al. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol. 1995;2(4):303-308.
4. Rittinger K, Divita G, Goody RS. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc Natl Acad Sci U S A. 1995;92(17):8046-8049.
5. Spence RA, Kati WM, Anderson KS, et al. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science. 1995;267(5200):988- 993.
6. Richman D, Shih C-K, Lowy I, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A. 1991;88:11241-11245.
7. Mellors JW, Dutschman GE, Im GJ, et al. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase [published erratum appears in Mol Pharmacol July 1992;42(1):174]. Mol Pharmacol. 1992;41(3):446-451.
8. Dueweke TJ, Pushkarskaya T, Poppe SM, et al. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci U S A. 1993;90(10):4713-4717.
9. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994;68(3):1660-1666.
10. Demeter LM, Shafer RW, Meehan PM, et al. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother. 2000;44(3):794-797.
11. Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother. 2000;44(9):2475-2484.
12. Gerondelis P, Archer RH, Palaniappan C, et al. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities. J Virol. 1999;73(7):5803-5813.
13. Archer RH, Dykes C, Gerondelis P, et al. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol. 2000;74(18):8390-8401.
14. Archer RH, Wisniewski M, Bambara RA, et al. The Y181C mutant of HIV-1 reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors alters the size distribution of RNase H cleavages. Biochemistry. 2001;40(13):4087-4095.
15. Palaniappan C, Wisniewski M, Jacques PS, et al. Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function. JBiol Chem. 1997;272(17):11157-11164.
16. Ghosh M, Jacques PS, Rodgers DW, et al. Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization. Biochemistry. 1996;35(26):8553-8562.
17. Jacques PS, Wohrl BM, Ottmann M, et al. Mutating the "primer grip" of p66 HIV-1 reverse transcriptase implicates tryptophan-229 in template-primer utilization. J Biol Chem. 1994;269(42):26472-26478.
18. Beard WA, Stahl SJ, Kim HR, et al. Structure/function studies of human immunodeficiency virus type 1 reverse transcriptase. Alanine scanning mutagenesis of an alpha-helix in the thumb subdomain. J Biol Chem. 1994;269(45):28091-28097.
19. Johnson KA. Rapid quench kinetic analysis of polymerases, adenosine triphosphatases, and enzyme intermediates. Methods Enzymol. 1995;249:38-61.
20. Patel SS, Wong I, Johnson KA. Pre-steady-state kinetic analysis of processive DNA replication including complete characterization of an exonuclease-deficient mutant. Biochemistry. 1991;30(2):511-525.
21. Kati WM, Johnson KA, Jerva LF, et al. Mechanism and fidelity of HIV reverse transcriptase. J Biol Chem. 1992;267(36):25988-25997.
22. Maga G, Amacker M, Ruel N, et al. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J Mol Biol. 1997;274(5):738-747.
23. Ren J, Esnouf R, Garman E, et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol. 1995;2(4):293-302.
24. Wisniewski M, Palaniappan C, Fu Z, et al. Mutations in the primer grip region of HIV reverse transcriptase can increase replication fidelity. J Biol Chem. 1999;274(40):28175-28184.
25. Jeffrey JL, Feng JY, Qi CC, et al. Dioxolane guanosine 5′-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses. J Biol Chem. 2003;278(21):18971-18979.
26. Tantillo C, Ding J, Jacobo-Molina A, et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Molec Biol. 1994;243(3):369-387.
27. Hopkins AL, Ren J, Esnouf RM, et al. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J Med Chem. 1996;39(8):1589-1600.
28. Krebs R, Immendorfer U, Thrall SH, et al. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC. Biochemistry. 1997; 36(33):10292-10300.
29. Spence RA, Anderson KS, Johnson KA. HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Biochemistry. 1996;35(3):1054-1063.
30. Kerr SG, Anderson KS. RNA dependent DNA replication fidelity of HIV-1 reverse transcriptase: evidence of discrimination between DNA and RNA substrates. Biochemistry. 1997;36(46):14056-14063.
31. Feng JY, Anderson KS. Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase. Biochemistry. 1999;38(1):55-63.
32. Ray AS, Basavapathruni A, Anderson KS. Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J Biol Chem. 2002;277(43):40479-40490.
33. Hsieh JC, Zinnen S, Modrich P. Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase. J Biol Chem. 1993;268(33):24607-24613.
34. Domaoal RA, Babmara RA, Demeter LM. HIV-1 reverse transcriptases resistant to non-nucleoside reverse transcriptase inhibitors have different effects on the kinetics of single nucleotide incorporation. Paper presented at: 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston, MA.
35. Ueno T, Mitsuya H. Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2′,3′-dideoxynucleotide analogs using the single-nucleotide incorporation assay. Biochemistry. 1997;36(5): 1092-1099.
36. Ueno T, Shirasaka T, Mitsuya H. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates. J Biol Chem. 1995;270(40):23605-23611.
37. Painter GR, Wright LL, Hopkins S, et al. Initial binding of 2′-deoxynucleoside 5′-triphosphates to human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem. 1991;266(29): 19362-19368.
38. Feng JY, Anderson KS. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry. 1999;38(29):9440-9448.
39. Wang J, Dykes C, Domaoal RA, Koval CE, Bambara RA, Demeter LM. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency. Virology. In press. Available online February 24, 2006 at http://www. sciencedirect.com/science/journal/00426822.